Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.48 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.48 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13879818 | 0.92 | KDM4E (0.49) | VNN1KDM4EALDH1A1HPGDNPC1 | |
| SCHEMBL14075894 | 0.90 | LMNA (0.53) | VNN1KDM4EALDH1A1HPGDNPC1 | |
| SCHEMBL22191080 | 0.84 | VNN1 (0.54) | VNN1KDM4EALDH1A1HPGDKCNH3 | |
| SCHEMBL14272901 | 0.79 | KDM4E (0.46) | KDM4EALDH1A1HPGD | |
| SCHEMBL13879795 | 0.79 | KDM4E (0.50) | VNN1KDM4EALDH1A1HPGD | |
| SCHEMBL21381218 | 0.79 | VNN1 (0.54) | VNN1KDM4EALDH1A1HPGDKCNH3 | |
| SCHEMBL14025733 | 0.78 | HIF1A (0.59) | VNN1HPGDNPC1RAB9A | |
| SCHEMBL10055036 | 0.77 | GPR55 (0.60) | KDM4EALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL14005187 | 0.76 | HDAC6 (0.43) | VNN1NPC1RAB9A | |
| SCHEMBL13879761 | 0.76 | KDM4E (0.43) | KDM4EALDH1A1HPGDNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8080659-B2 | CXCR4 antagonists including diazine and triazine structures for the treatment of medical disorders | EMORY UNIVERSITY (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080659-B2 | CXCR4 antagonists including diazine and triazine structures for the treatment of medical disorders | EMORY UNIVERSITY (US) | 2011-12-20 | — | — | US | disclosed |
| US-20090099194-A1 | CXCR4 Antagonists Including Diazine And Triazine Structures For The Treatment Of Medical Disorders | EMORY UNIVERSITY | 2009-04-16 | — | — | US | disclosed |
| US-20090099194-A1 | CXCR4 Antagonists Including Diazine And Triazine Structures For The Treatment Of Medical Disorders | EMORY UNIVERSITY | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099194-A1 | CXCR4 Antagonists Including Diazine And Triazine Structures For The Treatment Of Medical Disorders | CXCR4, CXCL12, CCR5 | VNN1 2369/4885KDM4E 3897/4885ALDH1A1 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.